GROUPE ATHENA, INC
MUMBAI, India, via ETELIGIS INC., 07/20/2015 – – Groupe Athena, Inc. (OTC Pink: GATA) (PINKSHEETS: GATA), is very excited to post the results for their fiscal year ending June 30, 2015. Annual revenue for the period was $70,867,148 which is an increase of 9% over the previous fiscal year and represents another new benchmark for the company. EBITDA for the year was also strong at $8,185,170 and net after tax income for the period was $4,613,321 or $.10 per share.
Current assets have risen to $19,192,620 as of June 30 and consist of primarily cash and short term investments. The company expects to use a substantial portion of their retained earnings to further continue their research & development initiatives.
Company Chairman, D. Purohit stated, “This is a very exciting time for Groupe Athena, Inc., as we develop new global and regional relationships, and as dynamics within our industry evolve, we are seeing many exciting opportunities unfold that we hope to capitalize on in the near to medium term.”
To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on “Financials”.
The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.
About Groupe Athena, Inc.
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.
The company has a research and marketing facility in India that currently employs 22 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company’s web address is www.groupeathena.com
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions — activities of competitors and the presence of new or additional competition and conditions of equity markets.
For more information contact:
Groupe Athena, Inc.
SOURCE: Groupe Athena, Inc.